When Is ADT Right for Biochemically Recurrent Prostate Cancer?

(MedPage Today) -- Men with prostate cancer and biochemical recurrence (BCR) who delayed androgen deprivation therapy (ADT) still experienced long survival outcomes, researchers reported.
In a retrospective study, men with a prostate-specific...